Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible.
Gristina V, La Mantia M, Peri M, Iacono F, Barraco N, Perez A, Viscardi G, Cutaia S, Russo TDB, Anwar Z, Incorvaia L, Fulfaro F, Vieni S, Pantuso G, Graceffa G, Russo A, Galvano A, Bazan V. Gristina V, et al. Among authors: bazan v. Crit Rev Oncol Hematol. 2023 Feb;182:103899. doi: 10.1016/j.critrevonc.2022.103899. Epub 2022 Dec 31. Crit Rev Oncol Hematol. 2023. PMID: 36596401 Free article. Review.
p53 mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: a prospective study with a five-year follow-up.
Russo A, Migliavacca M, Zanna I, Valerio MR, Latteri MA, Grassi N, Pantuso G, Salerno S, Dardanoni G, Albanese I, La Farina M, Tomasino RM, Gebbia N, Bazan V. Russo A, et al. Among authors: bazan v. Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1322-31. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12433709
The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N; TP53-CRC Collaborative Study Group. Russo A, et al. Among authors: bazan v. J Clin Oncol. 2005 Oct 20;23(30):7518-28. doi: 10.1200/JCO.2005.00.471. Epub 2005 Sep 19. J Clin Oncol. 2005. PMID: 16172461 Review.
Hereditary ovarian cancer.
Russo A, Calò V, Bruno L, Rizzo S, Bazan V, Di Fede G. Russo A, et al. Among authors: bazan v. Crit Rev Oncol Hematol. 2009 Jan;69(1):28-44. doi: 10.1016/j.critrevonc.2008.06.003. Epub 2008 Jul 24. Crit Rev Oncol Hematol. 2009. PMID: 18656380 Free article. Review.
Male breast cancer.
Ottini L, Palli D, Rizzo S, Federico M, Bazan V, Russo A. Ottini L, et al. Among authors: bazan v. Crit Rev Oncol Hematol. 2010 Feb;73(2):141-55. doi: 10.1016/j.critrevonc.2009.04.003. Epub 2009 May 7. Crit Rev Oncol Hematol. 2010. PMID: 19427229 Review.
Anti-endothelin drugs in solid tumors.
Russo A, Bronte G, Rizzo S, Fanale D, Di Gaudio F, Gebbia N, Bazan V. Russo A, et al. Among authors: bazan v. Expert Opin Emerg Drugs. 2010 Mar;15(1):27-40. doi: 10.1517/14728210903571667. Expert Opin Emerg Drugs. 2010. PMID: 20102289 Free article. Review.
257 results